Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults
Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults
Among the 278 healthy adults still enrolled in the trial, 96% maintained neutralizing antibody titers well above the seroresponse threshold three years after the single-dose vaccination. The primary endpoint was, therefore, met.On Tuesday, Valneva SE (NASDAQ:VALN) revealed antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ.
週二，Valneva SE（納斯達克:VALN）披露了其基孔肯雅IXCHIQ疫苗一劑接種後三年的抗體持久性數據。
The results align with Valneva's expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated.
這些結果與Valneva對該疫苗的預期一致，證實了所有年齡組中抗體持久性強且持久。
The three-year persistence data align with the twelve-month and two-year persistence data the company reported in December 2022 and 2023, respectively.
與公司分別在2022年12月和2023年12月公佈的12個月和兩年持久性數據一致。
Among the 278 healthy adults still enrolled in the trial, 96% maintained neutralizing antibody titers well above the seroresponse threshold three years after the single-dose vaccination. The primary endpoint was, therefore, met.
在仍在試驗中的278名健康成年人中，96%的人在單劑疫苗接種後三年保持了遠高於血清應答閾值的中和抗體滴度。主要終點因此得以滿足。
The persistence of antibodies in older adults (age 65+) in terms of geometric mean titers (GMTs) and seroresponse rates (SRRs) was comparable to younger adults (18-64 years of age).
老年人（65歲以上）的抗體持久性，即幾何均數滴度（GMT）和血清應答率（SRR），與年輕成年人（18-64歲）相當。
No safety concerns were reported or identified during the two-year follow-up, and no Adverse Event of Special Interest were ongoing during participant enrollment in the trial.
兩年後的隨訪中未報告或發現安全問題，並且在試驗期間，參與者報告沒有特殊興趣的不良事件。
IXCHIQ is the world's first and only licensed chikungunya vaccine.
IXCHIQ是世界上第一款也是唯一一款獲許可的基孔肯雅生物-疫苗。
The vaccine is currently approved in the U.S., Europe, and Canada to prevent disease caused by the chikungunya virus in individuals 18 and older.
生物-疫苗目前已在美國、歐洲和加拿大獲得批准，用於預防18歲及以上個體感染寨卡病毒引起的疾病。
Valneva recently submitted label extension applications to the FDA, the European Medicines Agency, and Health Canada to potentially extend the use of its chikungunya vaccine IXCHIQ to adolescents aged 12 to 17 years.
Valneva最近向FDA、歐洲藥品管理局和加拿大衛生部提交了IXCHIQ寨卡疫苗標籤擴展申請，以潛在地將其用於12至17歲青少年。
Juan Carlos Jaramillo, Chief Medical Officer of Valneva, said, "We are extremely pleased about these three-year data which further highlight IXCHIQ's differentiated product profile and ability to induce a robust, long-lasting antibody response in both younger and older adults with a single vaccination."
Valneva首席醫療官Juan Carlos Jaramillo表示：「我們對這三年的數據感到非常滿意，進一步凸顯了IXCHIQ不同於衆的產品特性，以及其能夠通過單次接種誘導出強有力且持久的抗體反應，無論是年輕人還是老年人。」
In September, Valneva and Pfizer Inc. (NYSE:PFE) released immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease vaccine candidate, VLA15, given one year after receiving the first booster dose.
9月，Valneva與輝瑞公司（紐交所：PFE）公佈了VLA15-221第2期研究的免疫原性和安全數據，這些數據是在接種他們的萊姆病候選疫苗VLA15的第二次加強劑後一年進行評估的。
One month after receiving the second booster dose, the immune response and safety profile of VLA15 were similar to those reported after receiving the first booster dose, showing compatibility with the anticipated benefit of a booster vaccination before each Lyme season.
在接種第二次加強劑後的一個月，VLA15的免疫反應和安全性與接種第一次加強劑後報告的情況相似，表明與每個萊姆病季之前進行加強接種的期望益處相契合。
Price Action: VALN stock is up 2.58% at $3.97 at last check Tuesday.
股價走勢：VALN股票最新報價爲3.97美元，週二最新漲幅爲2.58%。
譯文內容由第三人軟體翻譯。